{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:37:13Z","timestamp":1780335433363,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1124\/jpet.124.002199","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:12:23Z","timestamp":1719504743000},"page":"100003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quantification of cinpanemab (BIIB054) binding to \u03b1-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples"],"prefix":"10.1016","volume":"392","author":[{"given":"YuTing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weihofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren D.","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse M.","family":"Cedarbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Pepinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002199_bib1","first-page":"3139","article-title":"Evaluation of alpha-synuclein cerebrospinal fluid levels in several neurological disorders","volume":"11","author":"Agnello","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1124\/jpet.124.002199_bib2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson\u2019s disease","volume":"33","author":"Antonini","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.124.002199_bib3","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J\u00a0Neurosci"},{"key":"10.1124\/jpet.124.002199_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-023-00627-5","article-title":"CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease","volume":"10","author":"Brockmann","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1124\/jpet.124.002199_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.124.002199_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1124\/jpet.124.002199_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.124.002199_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2013a call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1124\/jpet.124.002199_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41382-0","article-title":"Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model","volume":"13","author":"Geerts","year":"2023","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.124.002199_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.37349\/ent.2023.00048","article-title":"Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease","volume":"3","author":"Henriquez","year":"2023","journal-title":"Explor Neuroprotective Ther"},{"key":"10.1124\/jpet.124.002199_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.124.002199_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/psp4.12538","article-title":"Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain","volume":"9","author":"Kuchimanchi","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.124.002199_bib13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/jpet.124.002199_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.124.002199_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating partially discordant results in phase 3 studies of Aducanumab","volume":"10","author":"Mallinckrodt","year":"2023","journal-title":"Prev Alzheimers Dis"},{"key":"10.1124\/jpet.124.002199_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1124\/jpet.124.002199_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jnc.14569","article-title":"Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study","volume":"149","author":"Mollenhauer","year":"2019","journal-title":"J\u00a0Neurochem"},{"key":"10.1124\/jpet.124.002199_bib18","first-page":"115","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of a-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog Basic Res"},{"key":"10.1124\/jpet.124.002199_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/jpet.124.002199_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.124.002199_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.124.002199_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/jpet.124.002199_bib23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"\u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies","volume":"33","author":"van Steenoven","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.124.002199_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T23:09:56Z","timestamp":1738278596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022356524000223"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002199","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of cinpanemab (BIIB054) binding to \u03b1-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100003"}}